During a walk following a November rain, Geoff Geiger paused by this Gingko tree in Central Alameda. He found the scent of ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

Ginkgo Bioworks Holdings, Inc.’s DNA share price has surged by 11.48%, which has investors questioning if this is right time to sell.

Ginkgo’s headquarters at 27 Drydock Ave. spans some 320,000 square feet, with leases that run from 2030 through 2036. The company has subleased 27,000 square feet, with another 129,000 square feet ...

But Ginkgo’s annual report filed on Tuesday shows the company also started subleasing part of its headquarters on Drydock Avenue in 2024. The company says its leases for the facility total over ...

Administration of Ginkgo biloba extract did not significantly improve IOP or other endpoints of interest among patients with ...

Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025.

Renowned for centuries, Ginkgo biloba is a well-known herbal supplement famed for its potential to bolster cognitive function, memory, and overall brain health. Sourced from the leaves of the ...

Sees FY25 Cell Engineering revenue $110M-$130M with potential upside from the recent launch of Tools offerings Ginkgo expects Biosecurity revenue in 2025 of at least $50M, representing approximate ...

Pre-earnings options volume in Ginkgo Bioworks (DNA) is normal with calls leading puts 8:5. Implied volatility suggests the market is anticipating a move near 17.6%, or $1.80, after results are ...

BOSTON, Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it ...